El Siglo

Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries

Retrieved on: 
Monday, February 6, 2023

SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary HempMeds® recently took part in a collaboration on a study to demonstrate the effectiveness of hemp-based cannabidiol (CBD) in the treatment of Parkinson's Disease.  The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries.

Key Points: 
  • The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries.
  • In this study, it was also shown that the application of CBD helps sensorimotor improvement,” Dr. Rocha stated.
  • Dr. Rocha added: “The results obtained in this study help to understand how the oral application of cannabidiol reduces excitotoxicity caused by long-term traumatic brain injuries and facilitates functional recovery.
  • HempMeds' commitment is to free access around the globe enabling people worldwide everyday to obtain the health benefits of cannabis-based products in an easy way.

Taylor® Guitars Revamps Its 700 Series With An All-Koa Lineup, Revealing A New Look, Feel And Sound While Expanding Its Palette Of Koa Models

Retrieved on: 
Thursday, May 26, 2022

EL CAJON, Calif., May 26, 2022 /PRNewswire-PRWeb/ -- Today, Taylor® Guitars, the leading global builder of premium acoustic guitars, unveils a sweeping change to its 700 Series, shifting from its longtime tonewood pairing of rosewood and spruce to all-Hawaiian-koa body construction. The reimagined series launches with two new guitar models: the Grand Auditorium 724ce and Grand Concert 722ce. The new all-koa 700 Series brings a uniquely compelling koa personality to the line compared to Taylor's existing, highly-figured Koa Series, channeling a more organic aesthetic. The new guitars feature new "Select-grade" koa wood that boasts rich color variegation and straight grain structure. Taylor master builder Andy Powers designed the guitars with ultra-thin matte finish and a modified back bracing pattern, a combination that minimizes the damping effect to produce a punchier, more vibrant and player-reflective koa guitar. The two new models are available now at authorized Taylor dealers worldwide.

Key Points: 
  • The new all-koa 700 Series brings a uniquely compelling koa personality to the line compared to Taylor's existing, highly-figured Koa Series, channeling a more organic aesthetic.
  • The new all-koa 700 Series builds upon Taylor's long history of using Hawaiian koa on guitars, dating back to the debut of its Koa Series in 1983, but intentionally offers a distinctive look, feel and musical personality compared to the iconic, ultra-premium Koa Series.
  • "For almost 40 years, Taylor has built a reputation crafting beautifully figured Koa Series guitars," says Andy Powers.
  • The koa 700s join a variety of existing koa wood guitars including the Koa Series, select 200 and 200 DLX Series models, GS Mini Koa and Koa Baby Taylor guitars.